GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perseus Proteomics Inc (TSE:4882) » Definitions » EV-to-EBIT

Perseus Proteomics (TSE:4882) EV-to-EBIT : -2.78 (As of May. 21, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Perseus Proteomics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Perseus Proteomics's Enterprise Value is 円2,538.02 Mil. Perseus Proteomics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was 円-911.51 Mil. Therefore, Perseus Proteomics's EV-to-EBIT for today is -2.78.

The historical rank and industry rank for Perseus Proteomics's EV-to-EBIT or its related term are showing as below:

TSE:4882' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.14   Med: -2.77   Max: -0.28
Current: -2.78

During the past 6 years, the highest EV-to-EBIT of Perseus Proteomics was -0.28. The lowest was -25.14. And the median was -2.77.

TSE:4882's EV-to-EBIT is ranked worse than
100% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.955 vs TSE:4882: -2.78

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Perseus Proteomics's Enterprise Value for the quarter that ended in Dec. 2023 was 円5,647.36 Mil. Perseus Proteomics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was 円-911.51 Mil. Perseus Proteomics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -16.14%.


Perseus Proteomics EV-to-EBIT Historical Data

The historical data trend for Perseus Proteomics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perseus Proteomics EV-to-EBIT Chart

Perseus Proteomics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBIT
Get a 7-Day Free Trial - - - -3.55 -1.52

Perseus Proteomics Quarterly Data
Mar18 Mar19 Dec19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.83 -1.52 -1.66 -4.33 -6.20

Competitive Comparison of Perseus Proteomics's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Perseus Proteomics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perseus Proteomics's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Perseus Proteomics's EV-to-EBIT falls into.



Perseus Proteomics EV-to-EBIT Calculation

Perseus Proteomics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2538.019/-911.505
=-2.78

Perseus Proteomics's current Enterprise Value is 円2,538.02 Mil.
Perseus Proteomics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-911.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perseus Proteomics  (TSE:4882) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Perseus Proteomics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-911.505/5647.364
=-16.14 %

Perseus Proteomics's Enterprise Value for the quarter that ended in Dec. 2023 was 円5,647.36 Mil.
Perseus Proteomics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-911.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perseus Proteomics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Perseus Proteomics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Perseus Proteomics (TSE:4882) Business Description

Traded in Other Exchanges
N/A
Address
4-7-6, Komaba, Tokyo Park Building, Meguro-ku, Tokyo, JPN, 153-0041
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody based therapeutics and diagnostics drugs to cure against cancer and other diseases.

Perseus Proteomics (TSE:4882) Headlines

No Headlines